What Trails Edge Capital Partners, LP reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 2077247 · Filed Nov 16, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 667K |
| +30.3% |
| $40M |
| 5.8% |
NRIXNurix Therapeutics, Inc. | 1.6M | ±0% | $37.3M | 5.4% |
OBXObsidian Therapeutics, Inc. | 2.5M | New | $34.3M | 4.9% |
IMCRImmunocore Holdings plc | 1.1M | ±0% | $32.2M | 4.6% |
FDMT4D Molecular Therapeutics, Inc. | 2.2M | ±0% | $31.9M | 4.6% |
DSGNDesign Therapeutics, Inc. | 2.5M | +24.9% | $31.4M | 4.5% |
CYTKCytokinetics Inc | 470K | +63.1% | $31M | 4.5% |
TRAXFirst Tracks Biotherapeutics, Inc. | 814K | −46.2% | $28.8M | 4.1% |
FTHFaeth Therapeutics, Inc. | 941.7K | +82.7% | $28M | 4% |
TNGXTango Therapeutics, Inc. | 1.1M | New | $27.4M | 3.9% |
NGNENeurogene Inc. | 964.9K | +35.0% | $26.8M | 3.9% |
CLDXCelldex Therapeutics, Inc. | 765K | New | $24.8M | 3.6% |
AVTXAvalo Therapeutics, Inc. | 1.5M | +68.2% | $23M | 3.3% |
CTNMContineum Therapeutics, Inc. | 1.7M | New | $22.7M | 3.3% |
TYRATyra Biosciences, Inc. | 1M | New | $21.9M | 3.1% |
MLTXMoonLake Immunotherapeutics | 1.7M | +124.0% | $19.7M | 2.8% |
IKTInhibikase Therapeutics, Inc. | 9.1M | +0.6% | $18.7M | 2.7% |
INBXInhibrx Biosciences, Inc. | 170K | New | $17M | 2.4% |
XENEXenon Pharmaceuticals Inc. | 400K | −9.1% | $14.9M | 2.1% |
CAMPCamp4 Therapeutics Corp | 3.6M | +87.6% | $14.6M | 2.1% |
ALTAltimmune, Inc. | 4.2M | +59.0% | $12.1M | 1.7% |
IRDOpus Genetics, Inc. | 2.4M | −12.1% | $11.7M | 1.7% |
KLRAKailera Therapeutics, Inc. | 943K | −4.2% | $10.8M | 1.5% |
SLGLSol-Gel Technologies Ltd. | 139.4K | ±0% | $10.4M | 1.5% |
IVAInventiva S.A. | 2.7M | ±0% | $9.8M | 1.4% |
TRDAEntrada Therapeutics, Inc. | 1.4M | New | $9.1M | 1.3% |
AURAAura Biosciences, Inc. | 1.4M | ±0% | $9.1M | 1.3% |
RACCResearch Alliance Corp III | 822.5K | +64.5% | $8.9M | 1.3% |
XFORX4 Pharmaceuticals, Inc | 2.6M | ±0% | $7.5M | 1.1% |
IPSCCentury Therapeutics, Inc. | 4.1M | ±0% | $7.1M | 1% |
PMNProMIS Neurosciences Inc. | 557.1K | ±0% | $6M | 0.9% |
RACDResearch Alliance Corp IV | 500K | New | $6M | 0.9% |
IMAImageneBio, Inc. | 1.1M | +288.0% | $5M | 0.7% |
NERVMinerva Neurosciences, Inc. | 1.4M | ±0% | $4.8M | 0.7% |
TCGXTCGX Acquisition Corp. | 250K | New | $3.1M | 0.4% |
VTVTvTv Therapeutics Inc. | 77K | −9.6% | $2.4M | 0.3% |
OKUROnKure Therapeutics, Inc. | 619.6K | −56.9% | $1.7M | 0.2% |